Interesting study on test and lipids, c-reactive protein, insulin and more
Sorry it is so lengthy, but I wanted everyone to see all of the study. Of course some of the figures couldn't format over on the change (if you want, you can pm me and I can figure out a way to let you see the original. It is on MDConsult, so if anone has a registration or membership, you can view it there)
I just wanted to point a few things out. First off, this a pretty valid study. It is a controlled, double blinded, randomized trial which is pretty much gold standard. There was appropriate time on AAS (20weeks) and a good followup (16 weeks). Pretty good sample size (of the 61, only 53 completed entire study). They also used a nice dosage range in the 5 groups: 25,50,125,300 and 600 mg of TestE/week. All of the participants were relatively young and healthy. Diets and exercise were kept pretty much constant and consistent between groups. And all men were chemically castrated before Test administration with a GnRH agonist, so endogenous Test can't factor into the equation and they are able to get a clean equal start among men.
Anyways, the good part is what the study set out to accomplish. The main outcome was to measure the baseline change in plasma lipids, apolipoproteins, insulin sensitivity, and C-reactive protein. All of which are indicated to play a role in coronary heart disease, and cardiovascular related morbidities and mortalities. If you can get through the study, I think you will find it pretty interesting. Only the 600mg/wk group showed any difference in significant clinical outcomes.
So try to read through it, and decide for yourself the usefulness of it. Remember though, this is just ONE study of 53 relatively normal, healthy men. But it is interesting nevertheless. If you have any questions, post em and lets discuss them.
136
Endocrine Care Of Special Interest to the Practice of Endocrinology
The Effects of Varying Doses of T on Insulin Sensitivity, Plasma Lipids, Apolipoproteins, and C-Reactive Protein in Healthy Young Men
ATAM B. SINGH 1
STANLEY HSIA 1
PETAR ALAUPOVIC 2
INDRANI SINHA-HIKIM 1
LINDA WOODHOUSE 1
THOMAS A. BUCHANAN 3
RUOQUING SHEN 1
RACHELLE BROSS 3
NANCY BERMAN 4
SHALENDER BHASIN 1
Abbreviations:
AIRG
Acute insulin response to glucoseCRP
Creactive proteinDI
glucose disposition indexHDL-C
high density lipoprotein cholesterolLDL-C
low density lipoprotein cholesterolSG
glucose effectiveness indexSI
insulin sensitivity indexVLDL-C
very low density lipoprotein cholesterol
The effects of T supplementation on insulin sensitivity, inflammation-sensitive markers, and apolipoproteins remain poorly understood. We do not know whether T's effects on plasma lipids, apolipoproteins, and insulin sensitivity are dose dependent, or whether significant anabolic effects can be achieved at T doses that do not adversely affect these cardiovascular risk factors. To determine the effects of different doses of T, 61 eugonadal men, 1835 yr of age, were randomly assigned to 1 of 5 groups to receive monthly injections of long-acting GnRH agonist to suppress endogenous T secretion and weekly injections of 25, 50, 125, 300, or 600 mg T enanthate for 20 wk. Dietary energy and protein intakes were standardized. Combined administration of GnRH agonist and graded doses of T enanthate resulted in nadir T concentrations of 253, 306, 542, 1345, and 2370 ng/dl at the 25-, 50-, 125-, 300-, and 600-mg doses, respectively. Plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations were inversely correlated with total and free T concentrations and were significantly decreased only in the 600 mg/wk group (change in high density lipoprotein cholesterol: −8 ± 2 mg/dl; P = 0.0005; change in apolipoprotein AI: −16 ± 2 mg/dl; P = 0.0001). Serum total cholesterol, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, triglycerides, apolipoprotein B, and apolipoprotein C-III were not significantly correlated with T dose or concentration. There was no significant change in total cholesterol, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, triglycerides, apolipoprotein B, or apolipoprotein C-III levels at any dose. The insulin sensitivity index, glucose effectiveness, and acute insulin response to glucose, derived from the insulin-modified, frequently sampled, iv glucose tolerance test using the Bergman minimal model, did not change significantly at any dose. Circulating levels of C-reactive protein were not correlated with T concentrations and did not change with treatment in any group. Significant increments in fat-free mass, muscle size, and strength were observed at doses that did not affect cardiovascular risk factors.
Over a wide range of doses, including those associated with significant gains in fat-free mass and muscle size, T had no adverse effect on insulin sensitivity, plasma lipids, apolipoproteins, or C-reactive protein. Only the highest dose of T (600 mg/wk) was associated with a reduction in plasma high density lipoprotein cholesterol and apolipoprotein AI. Long-term studies are needed to determine whether T supplementation of older men with low T levels affects atherosclerosis progression. ( J Clin Endocrinol Metab 87: 136143, 2002)
THERE IS CONSIDERABLE interest in exploring the use of T supplementation to prevent or reverse the loss of muscle mass and function, preserve bone mass, and improve health-related quality of life in older men with low T levels [1] [2] [3] [4] [5] [6] and in those with chronic diseases [7] . However, the risks and benefits of T supplementation remain poorly understood. Although T supplementation increases fat-free mass in healthy hypogonadal men [8] [9] [10] [11] [12] , older men with low T levels [2] [3] [4] [5] and human immunodeficiency virusinfected men with weight loss [7] , we do not know whether these beneficial effects can be achieved without adverse effects on the risk of cardiovascular disease.
Previous studies suggest that different androgen-dependent processes have different T dose requirements [13] [14] [15] [16] . Thus, sexual function can be maintained at T concentrations at the lower end of the normal male range [13] [14] [15] [16] ; in contrast, the effects of T on muscle mass and strength vary depending on T dose and circulating T concentrations [16] . It is not known whether clinically meaningful gains in muscle mass and strength can be achieved at T concentrations that do not adversely affect cardiovascular risk. Therefore, the objective of this study was to determine the dose-dependent effects of T on several risk factors of atherosclerotic heart disease in healthy young men. We wanted to determine the range of T doses and concentrations through which T could be safely administered without adversely affecting important cardiovascular risk factors, including plasma lipids, apolipoproteins, insulin sensitivity, and C-reactive protein (CRP).
The effects of T on insulin sensitivity remain controversial; some studies have suggested that physiological T replacement improves insulin sensitivity in middle-aged men with low T levels [17] [18] [19] . In contrast, administration of supra-physiological doses of T to castrated male rats [20] and of anabolic steroids to women [21] and power lifters [22] has
137
been shown to induce insulin resistance, suggesting that the relationship between circulating T concentrations and insulin sensitivity is complex. We considered the hypothesis that the relationship between serum T concentrations and insulin sensitivity is curvilinear, such that both subphysiological and supraphysiological T concentrations might adversely affect insulin sensitivity.
The inflammation-sensitive marker, CRP, has emerged as an important marker of cardiovascular risk that predicts the risk of heart disease independent of plasma lipids [23] . The effects of T on CRP have not been previously studied and were also the subject of this investigation.
In this study we investigated the relationship of T dose and concentrations to plasma levels of lipids, apolipoprotein, and CRP and measures of insulin sensitivity in healthy young men. Testicular T production was suppressed in healthy men by the administration of a long-acting GnRH agonist. We then created different circulating T concentrations by administering graded doses of T enanthate. In men in whom endogenous T production has been suppressed by GnRH agonist administration, circulating T concentrations are proportional to the administered T dose [16] . This approach minimizes the heterogeneity in serum T levels that results from varying degrees of suppression of endogenous T production by administration of exogenous androgen alone.
Subjects and Methods
Study design
This was a double blind, randomized study that consisted of a 4-wk control period, a 20-wk treatment period, and a 16-wk recovery period. The details of the study design have been previously described [16] .
Participants
Participants were healthy young men, 1835 yr of age, with normal serum T levels. These men were within 90120% of their ideal body weight. We excluded men with any known illness or those who had used androgenic steroids in the preceding year or were planning to participate in competitive sports events in the subsequent year. Each participant provided written, informed consent. The institutional review boards of Charles R. Drew University of Medicine and Science (Los Angeles, CA) and Harbor-University of California-Los Angeles Research and Education Institute (Torrance, CA) approved the study protocol.
Randomization
Sixty-one eligible men were randomly assigned to 1 of 5 treatment groups. All participants received monthly injections of a long-acting GnRH agonist (Decapeptyl, DebioPharm, R.P., Martigny, Switzerland) to suppress endogenous T production, starting on treatment d 1. In addition, group 1 received 25 mg T enanthate by im injection weekly, group 2 received 50 mg T enanthate weekly, group 3 received 125 mg T enanthate weekly, group 4 received 300 mg T enanthate weekly, and group 5 received 600 mg T enanthate weekly. T administration started on treatment d 1. These doses were selected to create and maintain T concentrations in a range that extended from low normal to supraphysiological levels for healthy young men. Twelve men were assigned each to groups 1, 2, and 3; 11 men were assigned to group 4; and 14 men were assigned to group 5. To assure compliance, the General Clinical Research Center staff administered the T and GnRH agonist injections.
Nutritional intake
For all participants, energy and protein intakes were standardized at 35 kcal/kgd and 1.2 g/kgd, respectively. The standardized diet was initiated 2 wk before the start of the treatment. Dietary instructions were reinforced every 4 wk by a nutritionist throughout the study. Adherence to dietary prescription was verified by analysis of 3-d food records and 24-h food recalls every 4 wk.
Exercise stimulus
The subjects were instructed to maintain their usual activity levels and not to undertake strength training or moderate to heavy endurance exercise during the study.
Outcome measures
The main outcome measures were change from baseline in plasma lipids, apolipoproteins, insulin sensitivity, and CRP.
Plasma levels of total cholesterol and triglycerides were determined enzymatically on an Abbott VP-Super System Analyzer, using commercially available reagents [CHOP/PAP, Roche (Mannheim, Germany), for total cholesterol, and Abbott Laboratories, Diagnostics Division (Irwing, TX), for triglycerides]. High density lipoprotein cholesterol (HDL-C) levels were measured by the modified heparin-manganese precipitation procedure of Warnick and Albers [24] .
Very low density lipoprotein cholesterol (VLDL-C), and low density lipoprotein cholesterol (LDL-C) levels were determined by the method of Friedewald et al. [25] . The quantification of apolipoproteins was performed by electroimmunoassay according to the previously described procedures for apolipoprotein A-I [26] , apolipoprotein B [27] , and apolipoprotein C-III [28] . All apolipoprotein measurements were carried out in triplicate. The inter- and intraassay coefficients of variation were 1.2% and 1% for apolipoprotein A-I, 1.3% and 1.2% for apolipoprotein B, and 1.7% and 1.2% for apolipoprotein C-III, respectively.
CRP was measured by a sensitive ELISA (DSL-10-42100 Active ELISA kit, Diagnostics Systems Laboratories, Inc., Webster, TX). Serum total and free T were measured periodically throughout the study. Serum total T levels were measured with an RIA that uses iodinated T as tracer [7] [29] [30] . This assay has a sensitivity of 0.44 ng/dl, and intra- and interassay coefficients of variation of 13.2% and 8.2%, respectively [30] . Free T was separated by an equilibrium dialysis procedure and then measured in the dialysate by an immunoassay [30] . The sensitivity of the free T assay is 0.6 pg/ml, and intra- and interassay coefficients of variation are 4.2% and 12.3%, respectively. Serum E2 levels were measured by an RIA with sensitivity of 2.5 pg/ml. Insulin concentrations were measured by RIA (ICN Biomedical, Inc., Costa Mesa, CA), with inter- and intraassay coefficients of variation of 6.8% and 11.5%, respectively. Plasma glucose levels were measured by the hexokinase-spectrophotometric method using reagents from Raichem, Inc. (San Diego, CA) and run on a Cobas Mira autoanalyzer (Global Medical Instrumentation, Clearwater, MN), giving inter- and intraassay of coefficients of variation of 3.8% and 6.8%, respectively. The lower limits of detection in plasma glucose and insulin assays were 10 mg/dl and 2.5 μU/ml, respectively.
The indexes for insulin sensitivity (SI ), glucose effectiveness (SG ), and acute insulin response to glucose (AIRG ) were derived from the frequently sampled, iv glucose tolerance test, using the Bergman minimal model [31] [32] . In this procedure insulin and plasma glucose measurements were performed on arterialized plasma obtained at baseline (−30 and −15 min), followed by an iv bolus of glucose (300 mg/kg BW) given within 2 min. Arterialized blood samples were collected at 2, 3, 4, 5, 8, 10, 18, and 20 min after iv glucose administration. An iv injection of regular recombinant human insulin (0.03 U/kg BW) was administered at 20 min, and additional arterialized blood samples were drawn at 28, 32, 40, 60, 70, 120, and 180 min for measurement of plasma insulin and glucose. SI , SG , and AIR G were derived from the minimal model program (version 3.0) using default parameters. The glucose disposition index was calculated as the product of SI and AIRG .
Statistical analyses
All variables were examined for their distribution characteristics. Variables that did not meet the assumption of a normal distribution or heterogeneity of variance were log-transformed and retested.
ANOVA was used to compare the change from baseline (change = posttreatment value minus pretreatment value) in the outcome measures among the five groups. If ANOVA revealed an overall significant
138
difference among groups, then those outcome measures were analyzed using paired t test to detect a nonzero change from baseline within each group. P < 0.05 was considered statistically significant; however, significance levels were adjusted for multiple comparisons using Bonferroni's correction.
The relationships between serum total and free T levels and each outcome measure were investigated using linear regression and correlation analyses. We also investigated the correlation between E2 and lipids using correlation analysis. To account for the effect of T on lipids, a multiple regression model, including both E2 and T as independent variables, was also run. The data are presented as the mean ± SEM.